Xenon Pharmaceuticals (XENE) is a clinical-stage biotech developing innovative therapies for neurology indications with a focus on epilepsy. At present, the company has no marketed drug in its portfolio. Xenon's pipeline comprises its lead product candidate, azetukalner, a differentiated Kv7 potassium channel, which is being developed for treating epilepsy and other neurological disorders, including major depressive disorder (MDD). Azetukalner is currently undergoing late-stage development for treating foca ...